Indium In 111 Pentreotide

Drug Levels and Effects:

Summary of Use during Lactation:

Electivediagnosticnuclear medicine procedures should be delayed until the patient is no longer breastfeeding.[1] Information in this record refers to the use of indium In 111 pentetreotide as adiagnosticagent. The International Commission on Radiological Protection states that breastfeeding need not be interrupted followingdiagnosticuse of In 111 pentetreotide.

In some cases, imaging with indium In 111 pentetreotide is followed shortly by a therapy (peptide receptor radiotherapy; PRRT) that uses yttrium 90 or lutetium 177 compounds to selectively irradiate tumors. These agents may pose additional radiation risk to the nursing infant.

Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital and when the radioactivity is at background levels, they may safely resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[2]

Drug Levels:

In 111 decays by electron capture with 171 and 245 keV gamma emissions and a physical half-life of 2.8 days.[3] The biological half-life of indium In-111 pentetreotide is 6 hours.[4]

Effects in Breastfed Infants:

Relevant published information was not found as of the revision date.

Possible Effects on Lactation:

Relevant published information was not found as of the revision date.


1. Parker JA, Daube-Witherspoon ME, Graham LS et al. Procedure guideline for general imaging: 3.0. Society of Nuclear Medicine. 2004.
2. Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: mechanisms, findings, and radiation dosimetry. J Nucl Med. 2000;41:863-73. PMID:10809203
3. Howe DB, Beardsley M, Bakhsh S. Appendix U. Model procedure for release of patients or human research subjects administered radioactive materials. In, NUREG-1556. Consolidated guidance about materials licenses. Program-specific guidance about medical use licenses. Final report. U.S. Nuclear Regulatory Commission Office of Nuclear Material Safety and Safeguards. 2008;9, Rev. 2.
4. Mallinckrodt Inc. OctreoScan product information. 2006;October 25.

Substance Identification:

Substance Name:

Indium In 111 Pentreotide

CAS Registry Number:


Drug Class:

  • Radiopharmaceuticals

  • Indium Radioisotopes

  • Administrative Information:

    LactMed Record Number:


    Last Revision Date:

    Disclaimer:Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.